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ABSTRACT.
Purpose: To compare treatment outcomes of treatment-na€ıve eyes with neovas-
cular age-related macular degeneration (nAMD) with bevacizumab as the first-
line treatment, according to the guidelines of the Dutch Ophthalmological
Society, with those treated first with either ranibizumab or aflibercept, as used in
many other countries, all treated using a treat-and-extend strategy.
Methods: Data were obtained from the prospectively designed Fight Retinal
Blindness! outcomes registry. The primary outcome was the mean change from
baseline in visual acuity of all treated eyes, after 12, 24 and 36 months of
treatment. Secondary outcomes were the number of injections, the number of
visits and the rate of switching to a second anti-VEGF drug.
Results: The study included 703 treatment-na€ıve eyes with nAMD with
12 months follow-up, 373 eyes with 24 months follow-up, and 171 eyes with
36 months follow-up in the Netherlands, and 1131, 652, and 303 treatment-na€ıve
eyes with respectively 12, 24, and 36 months of follow-up in all other countries.
The change in visual acuity from baseline did not differ between the Netherlands
and the other countries at any follow-up time. The median number of injections,
visits and the proportion of eyes switching treatment was significantly higher in
the Netherlands than in the other countries.
Conclusion: Starting anti-VEGF treatment for nAMD with bevacizumab, as is
mandatory in the Netherlands, delivers outcomes similar to those starting
treatment with either ranibizumab or aflibercept, but at a cost of more frequent
injections, and visits, and more frequent switching treatment to a second drug.
Key words: neovascular age-related macular degeneration (nAMD) – anti-VEGF treat-
ment – quality registration – real-world data
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Dutch ophthalmologists tended to use
bevacizumab as first-line anti-vascular
endothelial growth factor (anti-VEGF)
treatment to reduce costs for the
national healthcare system even before
several important comparative trials
had reported similar treatment out-
comes with bevacizumab and ranibizu-
mab for neovascular age-related
macular degeneration (nAMD) (Mar-
tin et al. 2012; Chakravarthy et al.
2013). After they were reported, the
Dutch Ophthalmological Society
issued an official guideline in 2014 that
advised all ophthalmologists to use
bevacizumab as the preferred drug to
start anti-VEGF treatment in nAMD,
with a revision in 2017 after a random-
ized clinical trial in the Netherlands
found that bevacizumab and ranibizu-
mab had similar outcomes (Schauwv-
lieghe et al. 2016; Society 2017).
Ophthalmologists in other parts of the
world, however, continued to use the
registered anti-VEGF drugs, either
ranibizumab or aflibercept, as first-line
treatment, instead of bevacizumab,
which was an off-label (not registered
for ocular use) drug. The question
arises whether the Dutch decision to
start with bevacizumab in nAMD
remains justified in ‘real-world’ clinical
practice, which often has outcomes
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that are different from those of ran-
domized clinical trials.
One way to evaluate this is to
compare data from a registry of anti-
VEGF treatment in nAMD patients
from the Netherlands with other coun-
tries with different treatment regimens.
A number of ophthalmological centres
in the Netherlands began to use the
nAMD module of the Fight Retinal
Blindness! Registry in 2015. This data-
base records real-world treatment out-
comes in patients with nAMD during
routine clinical practice through a web-
based interface (Gillies et al., 2014b,).
The registry, which has been endorsed
by ICHOM (International Consortium
for Health Outcomes Measurements)
to collect their minimum, patient-cen-
tred treatment outcomes of nAMD, is
used in Australia, New Zealand,
Switzerland and a growing number of
other countries (Rodrigues et al. 2016).
In the present study, 12, 24 and
36 months results of the treatment of
people with nAMD who were treated
in the participating FRB! centres in the
Netherlands, starting with beva-
cizumab, were compared to those of
centres in other countries, also using
the FRB! registry, where treatment was
started with either ranibizumab or
aflibercept. In addition, to prove the
value of benchmarking with the FRB!
registry, a comparison was made
between one of the Dutch participating
centres and all other participating cen-
tres in the Netherlands.
Methods
Data source
Thirteen centres in the Netherlands
started using the FRB! registry for the
treatment of wet AMD in 2015. New
patients were immediately entered con-
secutively at all participating centres,
and some centres chose to also ‘back
enter’ data on patients who started
treatment before 2015. For this study,
only patients starting their treatment in
2016 and onward were included in order
to prevent selectively entered data.
The mandatory, patient-centred,
minimum FRB! dataset was entered
through a web-based interface (Nguyen
et al. 2020).
The FRB! System collected the fol-
lowing data for each patient visit: the
number of letters read on a logarithm
of the minimum angle of resolution VA
chart (best of corrected, uncorrected or
pinhole visual acuity); the drug given;
activity of the choroidal neovascular
lesion as judged by the treating oph-
thalmologist based on fundoscopy,
OCT or FA alone or in combination
(an active lesion was defined as pres-
ence of intra- or subretinal fluid on
OCT, detection of a fresh haemor-
rhage, or leakage on FA), presence of
macular atrophy or fibrosis or pigment
epithelial detachment and ocular
adverse events. At baseline, in addition,
any previous treatment (all eyes in the
present study were treatment-naive),
lesion subtype based on imaging and
lesion size (greatest linear dimension,
on FA or OCT) was recorded (Bhan-
dari et al. 2020; Gillies et al.,
2020a,2020b; Nguyen et al. 2020).
Participants
Due to its noninterventional character,
approval of the use of the registry was
not needed according to the Medical
Ethics Committee of the Academic
Medical University Centre, the Nether-
lands. All patients had to sign an
informed consent before data were
entered in the registry. The FRB!
project adhered to the tenets of the
Declaration of Helsinki.
Treatment-na€ıve eyes with nAMD
that were registered into the FRB!
database in the Netherlands from Jan-
uary 2016 onwards that received beva-
cizumab at the start of the treatment as
required by the Dutch guideline, with
at least 12, 24 or 36 months of follow-
up, were included in this study.
Patients entering the registry up until
1 January 2019 were considered for the
12-month end-point, 1 January 2018
for the 24-month end-point, and 1
January 2017 for the 36-month end-
point to accurately determine the com-
pletion and dropout rate.
These eyes were compared to all the
treatment-na€ıve eyes with nAMD, reg-
istered in the FRB! registry in the same
time period that were treated in Aus-
tralia, New Zealand or Switzerland
(hereafter referred to as ‘rest of
FRB!’), and started treatment with
either ranibizumab or aflibercept with
identical follow-up periods. We also
made the same comparison between
one of the participating centres, which
entered the highest number of patients,
in the Netherlands and all the other
Dutch centres.
Outcome measures
The primary outcome measure was the
change in VA from baseline at 12, 24
and 36 months. Secondary outcomes
included the number of injections, the
number of visits and the number of
patients switching to another anti-
VEGF drug during the 36 months
follow-up period.
Statistical analysis
All analyses were performed using R
version 4.0.0 (R Project – The R
Foundation for Statistical Computing,
Vienna, Austria). Descriptive statistics
included mean, standard deviation
(SD), median, range, quartiles and
percentages where appropriate.
A LOESS (locally estimated scatter-
plot smoothing) curve was used to plot
the visual acuity over time (Cleveland
2017). Unadjusted outcomes were com-
pared using t-tests and chi-squared
tests where appropriate. Adjusted
change in VA was compared using
mixed-effects regression models. The
number of injections and visits was
compared using generalized Poisson
regression models with an offset for
log days of follow-up. Analyses of time
to switching to another anti-VEGF
drug were performed using Cox pro-
portional hazards models. All models
included adjustments for age and VA
at baseline (fixed effects) and nesting of
outcomes within doctors (for the
Netherlands versus rest of FRB! anal-
ysis only) and patients with both eyes
included (random effects).
Results
The Netherlands versus the rest of FRB!
This study included 703/851 eyes (17%
dropout rate) from 623/748 patients
treated at the participating centres in
the Netherlands with at least
12 months follow-up, 373/526 eyes
(29% dropout rate) from 331/462
patients with at least 24 months fol-
low-up, and 171/249 eyes (31% drop-
out rate) from 153/225 patients with at
least 36 months follow-up. From the
rest of FRB! cohort, 1131/1448 treat-
ment-na€ıve eyes (22% dropout rate)
from 1009/1279 patients were included
with at least 12 months follow-up, 652/
1014 eyes (36% dropout rate) from
594/918 patients with at least
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24 months follow-up, and 303/446 eyes
(37% dropout rate) from 278/483
patients with at least 36 months fol-
low-up. Baseline demographics are
summarized in Table 1.
Baseline characteristics were similar
between both groups for the 12-month,
the 24-month and the 36-month com-
pleters.
The lesion size at baseline did not
differ between the eyes treated in the
Netherlands and the eyes treated in the
other countries for the 12-month, the
24-month, and the 36-month com-
pleters, but the longer the follow-up
the smaller the lesion size at baseline,
going from around 1700 micron to
1500 micron.
The angiographic typing of the neo-
vascular lesion was not done in most of
the eyes so this information is only of
limited use; however, lesion types
between the Netherlands and the other
countries were broadly similar.
Visual and treatment outcomes are
summarized in Table 2. The mean
(95% CI) unadjusted change in VA
from baseline to 12, 24 and 36 months
was 5.6 (4.3, 6.8), 6.1 (4.4, 7.7) and 5.7
(3.2, 8.2) letters in the Netherlands
versus 5.1 (4.2, 5.9), 3.5 (2.3, 4.8) and
2.7 (0.8, 4.7) letters in the other coun-
tries, respectively. The change in VA
(number of letters read) from baseline
to 12, 24 and 36 months seemed better
in the Netherlands, but the difference
was only statistically significant
(p = 0.017) for the 24 months com-
pleters. After adjusting the numbers for
baseline visual acuity, age and nesting
of outcomes from patients within treat-
ing ophthalmologists, the change in
visual acuity from baseline did not
differ between the Netherlands and
the other countries at any point,
including the proportions of eyes with
a gain or loss of at least 10 or 15 letters.
The change in visual acuity over
36 months is shown in Fig. 1. The
curve from the Dutch patients
improved less steeply than that of the
other countries, with similar mean
visual acuity after the first 12 months
between the 2 groups.
The number of injections after mul-
tivariate adjustment was significantly
higher in the Netherlands than in the
rest of FRB! for the 12-month, the 24-
month, and the 36-month completers.
The median (Q1, Q3) number of injec-
tions for the Netherlands versus rest of
FRB! was 10 (8, 12) versus 8 (7, 10)
(p = 0.001) injections at 12 months, 18
(13, 23) versus 14 (11, 17) (p = 0.015)
injections at 24 months, and 26 (20, 33)
versus 20 (16, 25) (p = 0.001) at
36 months. This trend was also
observed for the number of visits at
all time-points (Table 2).
The proportion of eyes switching
treatment was significantly higher in
the Netherlands than in the other
countries. The percentage of switchers
for the Netherlands versus rest of FRB!
was 26% versus 16% (p < 0.001) at
12 months, 45% versus 22%
(p = 0.005) at 24 months, and 59%
and 29% (p = 0.010) at 36 months.
The majority of switching in both the
Netherlands and rest of FRB! was to
aflibercept.
The number of adverse events,
counting all events occurring within
the 3 years of follow-up, for all eligible
eyes, including the dropouts, was low,
and did not differ significantly between
the Netherlands and the rest of FRB!.
In total, 17 965 injections were
recorded in the Netherlands and
21 397 in the rest of FRB! Hae-
morhage reducing BCVA > 15 letters
was seen in 6 cases in the Netherlands
(0.042%), versus 10 cases in the rest of
FRB! (0.052%), infectious endoph-
thalmitis in 2 (0.014%), versus 1
(0.005%) cases, noninfectious endoph-
thalmitis in 7 (0.049%) versus 0 (0%)
cases, and RPE tear in 16 (0.113%)
versus 21 (0.11%) cases.
Benchmarking versus the rest of the
Netherlands
A comparison could be made using the
same data between one of the centres in
the Netherlands (Centre A) that
included most patients during the fol-
low-up period and the rest of the
Table 1. Baseline demographics for the Netherlands versus rest of FRB!.
12-Month Completers 24-Month Completers 36-Month Completers
Netherlands Rest of FRB! Netherlands Rest of FRB! Netherlands Rest of FRB!
Eyes 703 1131 373 652 171 303
Patients 623 1009 331 594 153 278
Gender, % female patients 62.1% 62.2% 61.6% 64.3% 64.1% 66.9%
Age, mean (SD) 79.1 (8.3) 80.6 (8.2) 78.6 (8.1) 80.6 (7.8) 77.9 (8.8) 80.6 (7.8)
VA, mean letters (SD) 59.2 (18.4) 60.7 (18.6) 59.3 (17.4) 61.7 (17.3) 58.7 (18.6) 61.4 (17.2)
VA ≤ 35 letters, n (%) 82 (11.7%) 123 (10.9%) 40 (10.7%) 59 (9%) 20 (11.7%) 27 (8.9%)
VA ≥ 70 letters, n (%) 249 (35.4%) 463 (40.9%) 127 (34%) 274 (42%) 62 (36.3%) 127 (41.9%)
Lesion size, median µm (Q1, Q3) 1759 (600, 3000) 1700 (1000, 2580) 1750 (500, 3000) 1600 (1033, 2579) 1576 (500, 2400) 1500 (1000, 2384)
Angiographic lesion type, n (%)
Type 1 186 (26.5%) 478 (42.3%) 119 (31.9%) 328 (50.3%) 57 (33.3%) 171 (56.4%)
Type 2 44 (6.3%) 135 (11.9%) 20 (5.4%) 86 (13.2%) 8 (4.7%) 52 (17.2%)
Type 3 5 (0.7%) 37 (3.3%) 1 (0.3%) 22 (3.4%) 1 (0.6%) 11 (3.6%)
Disciform scar 3 (0.4%) 3 (0.3%) 0 (0%) 3 (0.5%) 0 (0%) 1 (0.3%)
IPCV 3 (0.4%) 10 (0.9%) 3 (0.8%) 5 (0.8%) 1 (0.6%) 3 (1%)
Juxtapapillary 12 (1.7%) 15 (1.3%) 6 (1.6%) 7 (1.1%) 2 (1.2%) 3 (1%)
Not done 450 (64%) 453 (40.1%) 224 (60.1%) 201 (30.8%) 102 (59.6%) 62 (20.5%)
Initial injection type, n (%)
Avastin 703 (100%) 0 (0%) 373 (100%) 0 (0%) 171 (100%) 0 (0%)
Eylea 0 (0%) 571 (50.5%) 0 (0%) 329 (50.5%) 0 (0%) 128 (42.2%)
Lucentis 0 (0%) 560 (49.5%) 0 (0%) 323 (49.5%) 0 (0%) 175 (57.8%)
3
Acta Ophthalmologica 2020
Netherlands. In Centre A, 257 eyes had
at least 12 months follow-up, 153 eyes
at least 24 months follow-up, and 74
eyes at least 36 months of follow-up. In
rest of the Netherlands, 446 treatment-
na€ıve eyes were included with at least
12, 220 eyes with at least 24, and 97
eyes with at least 36 months of follow-
up, respectively. Baseline demograph-
ics of both groups of patients are
summarized in Table 3.
Their baseline characteristics
between Centre A and the rest of the
Netherlands were similar.
The lesion size at baseline did not
differ between the eyes treated in centre
A and the eyes treated in the rest of the
Netherlands for the 12-month, the 24-
month, and the 36 month completers.
The median lesion size was 1500
micron in centre A for the 12-month
completers, and 2000 micron for the
rest of the Netherlands; for the
24 months completers, these numbers
were 1500 micron and 1954 micron,
Table 2. Outcomes at 12, 24 and 36 months comparing Netherlands versus rest of FRB! for treatment-na€ıve eyes initiating treatment from 2016













Eyes 703 1131 373 652 171 303
Baseline VA, mean letters (SD) 59.2 (18.4) 60.7 (18.6) 0.105 59.3 (17.4) 61.7 (17.3) 0.035 58.7 (18.6) 61.4 (17.2) 0.119
Final VA, mean letters (SD) 64.8 (18.1) 65.7 (18.8) 0.286 65.4 (17.4) 65.2 (19.9) 0.891 64.4 (17.1) 64.1 (20.7) 0.868























42%/7.5% 0.253* 36.3%/52% 41.9% /
53.1%
0.895*
VA change, mean (95% CI) 5.6 (4.3, 6.8) 5.1 (4.2,
5.9)
0.519 6.1 (4.4, 7.7) 3.5 (2.3,
4.8)
0.017 5.7 (3.2, 8.2) 2.7 (0.8, 4.7) 0.064




0.045 60 (35.1%) 90 (29.7%) 0.268
≥10 letter loss, n (%) 84 (11.9%) 128
(11.3%)
0.737 41 (11%) 89 (13.7%) 0.257 23 (13.5%) 53 (17.5%) 0.307




0.019 39 (22.8%) 65 (21.5%) 0.821
≥15 letter loss, n (%) 54 (7.7%) 67 (5.9%) 0.168 30 (8%) 60 (9.2%) 0.606 12 (7%) 33 (10.9%) 0.223
Adjusted VA change, mean
(95% CI)
4.5 (3.0, 6.1) 5.4 (4.4,
6.3)
0.357 4.7 (2.6, 6.9) 3.9 (2.6,
5.2)
0.532 4.4 (1.5, 7.3) 3.3 (1.4, 5.3) 0.541
Injections, median (Q1, Q3) 10 (8, 12) 8 (7, 10) 0.001† 18 (13, 23) 14 (11, 17) 0.015† 26 (20, 33) 20 (16, 25) 0.001†
Visits, median (Q1, Q3) 13 (11, 15) 9 (8, 10) <0.001† 23 (18, 27) 15 (12, 18) <0.001† 34 (25.5, 40) 21 (17, 26) <0.001†
Switched, n (%) 185 (26.3%) 180
(15.9%)
<0.001† 169 (45.3%) 142
(21.8%)
0.005† 100 (58.5%) 87 (28.7%) 0.010†
To Avastin 0 (0%) 7 (0.6%) 0 (0%) 7 (1.1%) 0 (0%) 5 (1.7%)
To Eylea 149 (21.2%) 138
(12.2%)
136 (36.5%) 111 (17%) 78 (45.6%) 69 (22.8%)
To Lucentis 36 (5.1%) 35 (3.1%) 33 (8.8%) 24 (3.7%) 22 (12.9%) 13 (4.3%)
Significant differences in bold.
CI = confidence interval; Q1 = first quartile (25th percentile); Q3 = third quartile (75th percentile); SD = standard deviation; VA = visual acuity
* p-values comparing percentages for final visual acuity
† p-value from mixed-effects regression models, generalized Poisson regression models, or Cox proportional hazards models adjusted for baseline
visual acuity, age and nesting of outcomes from patients within treating ophthalmologists
Fig. 1. Locally weighted scatterplot smoothing (LOESS) regression curve of mean visual acuity
for treatment-na€ıve eyes initiating treatment from 2016 onwards completing 36 months of
treatment comparing Netherlands versus Rest of FRB!
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and for the 36 months completers 1350
and 1750 micron.
The angiographic typing of the
lesion provides only limited informa-
tion because was not done in most eyes.
There were no obvious differences
between the two groups.
Visual and treatment outcomes are
summarized in Table 2. The mean
(95% CI) unadjusted change in VA
from baseline to 12, 24 and 36 months
was 7.8 (5.7, 9.9), 8.5 (6.2, 10.9) and 7.1
(4.0, 10.1) letters in centre A versus 4.3
(2.8, 5.8), 4.4 (95% CI 2.1, 6.7) and 4.7
(95% CI 0.9, 8.5) letters in the rest of
the Netherlands, respectively. These
differences were significant at
12 months (p = 0.008) and 24 months
(p = 0.013). This difference in change
in visual acuity from baseline remained
significant after multivariate adjust-
ment at 12 months (p = 0.003) and
24 months (p = 0.02). Visual acuity
over the 36 months is shown Fig. 2.
The number of injections after mul-
tivariate adjustment was significantly
higher in Centre A compared to the
rest of the Netherlands for the 12-, 24-
and 36-month completers. The median
(Q1, Q3) number of injections for
Centre A versus the rest of Netherlands
was 12 (10, 13) versus 9 (8, 11)
(p < 0.001) injections at 12 months,
21 (15, 25) versus 17 (12, 20)
(p < 0.001) injections at 24 months,
and 31 (21, 35) versus 25 (19, 30)
(p = 0.022) injections at 36 months.
This trend was also observed for the
number of visits at all time-points
(Table 4).
The proportions switching treatment
were not significantly different between
Centre A and the rest of the Nether-
lands (around 25% of both groups in
the 12-month completers, 45% of the
24-month completers, and 49% in the
36-month completers from Centre A
compared with 66% in the rest of the
Netherlands.
Discussion
This analysis of a prospectively
designed outcomes registry showed
the results of treatment of nAMD with
anti-VEGF in the Netherlands starting
obligatorily, according to the Dutch
guidelines, with bevacizumab were
comparable with results in other coun-
tries starting with either ranibizumab
or aflibercept at 12, 24 and 36 months,
but at the cost of more frequent injec-
tions and visits. Switching treatment to
a second drug was also more prevalent
in the Netherlands. Using the same
data to compare the results of a single
Dutch centre with the rest of the Dutch
FRB! centres, we found better visual
outcomes in this centre, again at a cost
of more frequent injections and visits.
The FRB! registry is a powerful tool to
perform benchmarking clinical
outcomes between different countries
and centres who may be using different
treatment guidelines and drugs.
The treatment strategy used in the
Netherlands and in the other countries
belonging to the comparison group was
treat-and-extend. All treatment deci-
sions were made by individual ophthal-
mologists without guidance from a
central reading centre enforcing strict
retreatment criteria. A comparison of
treatments between groups of patients
may therefore be biased by inconsis-
tencies in treatment decisions. As the
T&E treatment interval increment cri-
teria were not standardized, compar-
ison on treatment burden between the
clinics/countries may better reflect vari-
ation how T&E is executed, rather than
properties of the used anti-VEGF drug
itself.
However, the treatment results pre-
sented in this study are in line with
other similar studies on treat-and-ex-
tend regimes (Berg et al. 2015; Berg
et al. 2016; Gerding 2016; Kim et al.
2016; Ohji et al. 2020).
Recent meta-analyses of 2-year and
3-year results following a treat-and-
extend strategy with either ranibizu-
mab or aflibercept found similar gains
in visual acuity from baseline: after
12 months between 4.5 and 5.7 letters,
after 24 months between 4.7 and 7.6
letters, and after 36 months between
2.2 and 3.5 letters. The mean number
Table 3. Baseline demographics for Centre A versus the rest of the Netherlands.








Eyes 257 446 153 220 74 97
Patients 231 392 138 193 68 85
Gender, % female patients 60.2% 63.3% 58% 64.2% 63.2% 64.7%
Age, mean (SD) 78.9 (9.2) 79.2 (7.8) 78.9 (9.1) 78.3 (7.4) 78 (9.9) 77.7 (7.9)
VA, mean letters (SD) 59.1 (16.2) 59.3 (19.6) 58.3 (15.3) 60 (18.8) 58.4 (14.9) 58.9 (21.1)
VA ≤ 35 letters, n (%) 21 (8.2%) 61 (13.7%) 13 (8.5%) 27 (12.3%) 5 (6.8%) 15 (15.5%)
VA ≥ 70 letters, n (%) 78 (30.4%) 171 (38.3%) 43 (28.1%) 84 (38.2%) 20 (27%) 42 (43.3%)




2000 (750, 3108) 1500 (366,
2500)
1955 (735, 3164) 1350 (500,
2400)
1750 (600, 2926)
Angiographic lesion type, n (%)
Type 1 29 (11.3%) 157 (35.2%) 20 (13.1%) 99 (45%) 9 (12.2%) 48 (49.5%)
Type 2 4 (1.6%) 40 (9%) 4 (2.6%) 16 (7.3%) 2 (2.7%) 6 (6.2%)
Type 3 0 (0%) 5 (1.1%) 0 (0%) 1 (0.5%) 0 (0%) 1 (1%)
Disciform scar 0 (0%) 3 (0.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
IPCV 0 (0%) 3 (0.7%) 0 (0%) 3 (1.4%) 0 (0%) 1 (1%)
Juxtapapillary 8 (3.1%) 4 (0.9%) 2 (1.3%) 4 (1.8%) 1 (1.4%) 1 (1%)
Not done 216 (84%) 234 (52.5%) 127 (83%) 97 (44.1%) 62 (83.8%) 40 (41.2%)
5
Acta Ophthalmologica 2020
of injections given was 6.5 in the first
year, 4.5 in the second year and 4.0 in
the third year (Gerding 2016; Kim et al.
2016; Ohji et al. 2020).
In the LUCAS study comparing
results of treatment with bevacizumab
versus ranibizumab according to a
treat-and extend regime, the gain in
VA from baseline after 1 year was
comparable between the two groups,
around 8.0 letters, around 7.0 letters
after 2 years, in both groups, but with
significantly more injections needed in
the bevacizumab group: 8.9 in the first
year and 18.2 in two years compared
with 8.0 in the first year, and 16.0 in the
second year, for ranibizumab. (Berg
et al. 2015; Berg et al. 2016).
One may conclude that analysis of
the data collected in routine clinical
practice through the FRB! registry
found largely comparable outcomes
with regard to mean visual acuity gain
at 12, 24 and 36 months of follow-up
in the Netherlands and the rest of
FRB! The number of injections was
higher in the present study not only in
the Netherlands, but also in the rest of
FRB, for all follow-up periods. A
previous study using the FRB! registry
found that results from routine patient
care were similar to those of a pivotal
drug registration study if the observa-
tional cohort was filtered in the same
way as the clinical trial (Gillies et al.,
2014a).
The gain in mean visual acuity was
faster in the first year in the other
countries than in the Netherlands (see
Fig. 1). This observation mirrors the
results of the DRCR network study of
the treatment of diabetic macular
oedema with different anti-VEGF
drugs, where bevacizumab treated eyes
responded with a slower rise to the
maximum visual acuity gain than
ranibizumab- or aflibercept-treated
eyes (Wells et al. 2016).
The small number of centres in the
Netherlands participating in this study
is a small sample of all the centres in
the Netherlands treating nAMD, and
therefore, it may not fully represent
the entire country. It is possible that
the participating centres were highly
motivated to reach the best possible
treatment results and therefore less
tolerant of persistently active lesions,
which could lead to a higher number
of injections and visits compared to
the general standard ophthalmological
practice in the Netherlands. Several
studies have demonstrated that the
best results are achieved in patients
treated with the highest number of
injections irrespective of the drug used
(Holz et al. 2015). The differences
found in the present study could be
simply due to the high number of
injections and not caused by the
difference in the drug, which was
mainly bevacizumab in the
Netherlands, and ranibizumab or
aflibercept in the rest of FRB!.
General cardiovascular or other
complications were not recorded in
the registry. The number of ocular
adverse events such as endophthalmitis
was very low and seemed unrelated to
the total number of injections. How-
ever, there were more incidences of
noninfectious endophthalmitis in the
Netherlands cohort compared with the
rest of FRB! which is likely due to the
use of bevacizumab as was reported in
a previous FRB! analysis (Daien et al.
2018).
Many eyes in the Netherlands were
switched to a second drug. Consistent
with other studies, most switches were
made to aflibercept (Barthelmes et al.
2016; Barthelmes et al. 2018). Switch-
ing was more frequent in the Nether-
lands than in the other countries. The
indication to switch was based on the
impression of the treating ophthalmol-
ogist that the first drug was not effec-
tive. This could be because visual
acuity did not improve, the OCT failed
to show an effect on retinal fluid, or the
interval between injections could not be
extended beyond 4 weeks. The precise
reasons are not documented, but the
higher proportion switching in the
Netherlands, where they started with
bevacizumab, suggests bevacizumab
may be less effective than aflibercept
or ranibizumab, the starting drug in the
other countries. Practitioners’ percep-
tion of the relative efficacy of the
different drugs may also have con-
tributed to the higher switching rate
in the Netherlands.
It would be interesting to include
results of clinical practices in other
countries having national guidelines for
bevacizumab as a first-line agent to
substantiate the results of the present
study.
We have analysed this in more detail
for all patients who switched treatment
in the Netherlands (see Table 5). The
VA at the switch was considerably
higher than at baseline. The final VA
after switch was slightly higher than at
the switch, so it appears there was still
room for improvement even after a
relatively long period of injections
before the switch.
We have also analysed the median
number of injections per year before
and after the switch. The injection rates
fell after the switch, but only by ~1
injection per year which seems only a
Fig. 2. Locally weighted scatterplot smoothing (LOESS) regression curve of mean visual acuity
for treatment-na€ıve eyes initiating treatment from 2016 onwards completing 36 months of
treatment comparing Centre A versus Rest of Netherlands
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Table 4. Outcomes at 12, 24 and 36 months comparing a single centre in the Netherlands versus the other centres in the Netherlands for treatment-
na€ıve eyes initiating treatment from 2016 onwards completing 12, 24 and 36 months of treatment respectively
12 Months 24 Months 36 Months
Centre A
Rest of
Netherlands p-value Centre A
Rest of
Netherlands p-value Centre A
Rest of
Netherlands p-value




59.1 (16.2) 59.3 (19.6) 0.858 58.3 (15.3) 60 (18.8) 0.333 58.4 (14.9) 58.9 (21.1) 0.861
Final VA, mean
letters (SD)
66.9 (15.1) 63.6 (19.5) 0.012 66.8 (13.6) 64.4 (19.5) 0.155 65.5 (13.1) 63.6 (19.6) 0.462
≤35 letters, %
baseline/% final
8.2%/4.7% 13.7%/12.8% <0.001* 8.5%/3.3% 12.3%/13.2% 0.002* 6.8%/4.1% 15.5%/12.4% 0.103*
≥70 letters, %
baseline/% final
30.4%/51.8% 38.3%/55.4% 0.395* 28.1%/48.4% 38.2%/57.3% 0.112* 27%/41.9% 43.3%/59.8% 0.030*
VA change, mean
(95% CI)
7.8 (5.7, 9.9) 4.3 (2.8, 5.8) 0.008 8.5 (6.2, 10.9) 4.4 (2.1, 6.7) 0.013 7.1 (4, 10.1) 4.7 (0.9, 8.5) 0.334
≥10 letter gain,
n (%)
115 (44.7%) 144 (32.3%) 0.001 69 (45.1%) 75 (34.1%) 0.041 25 (33.8%) 35 (36.1%) 0.881
≥10 letter loss, n
(%)
22 (8.6%) 62 (13.9%) 0.048 13 (8.5%) 28 (12.7%) 0.264 8 (10.8%) 15 (15.5%) 0.511
≥15 letter gain,
n (%)
69 (26.8%) 95 (21.3%) 0.114 47 (30.7%) 55 (25%) 0.271 15 (20.3%) 24 (24.7%) 0.612
≥15 letter loss, n
(%)




7.7 (5.9, 9.5) 4.3 (2.9, 5.7) 0.003 8.1 (5.9, 10.4) 4.6 (2.7, 6.5) 0.020 7.0 (3.8, 10.2) 4.8 (2.0, 7.6) 0.314
Injections,
median (Q1, Q3)
12 (10, 13) 9 (8, 11) <0.001† 21 (15, 25) 17 (12, 20.2) <0.001† 31 (21, 35) 25 (19, 30) 0.022†
Visits, median
(Q1, Q3)
12 (10, 14) 14 (12, 16) <0.001† 22 (17, 25) 24 (19, 30) <0.001† 31 (22, 35.8) 37 (31, 44) <0.001†
Switched, n (%) 66 (25.7%) 119 (26.7%) 0.094† 66 (43.1%) 103 (46.8%) 0.130† 36 (48.6%) 64 (66%) 0.095†
To Avastin 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
To Eylea 66(25.7%) 83 (18.6%) 6643.1%) 70 (31.8%) 36 48.6%) 42 (43.3%)
To Lucentis 0 (0%) 36 (8.1%) 0 (0%) 33 (15%) 0 (0%) 22 (22.7%)
CI = confidence interval; Q1 = first quartile (25th percentile); Q3 = third quartile (75th percentile); SD = standard deviation; VA = visual acuity.
* p-values comparing percentages for final visual acuity.
† p-value from mixed-effects regression models, generalized poisson regression models, or Cox proportional hazards models adjusted for baseline
visual acuity, age and nesting of outcomes from patients within treating ophthalmologists.
Table 5. Treatment results for patients who switched therapy in the Netherlands













Eyes 36 149 33 136 22 78
Baseline VA, mean letters (SD) 62.1 (14.4) 59.7 (17.6) 63.8 (14.4) 57.3 (17.8) 61.9 (17.1) 57.5 (19.1)
VA at switch 67.4 (15.4) 63.9 (16.4) 65.8 (17.1) 63.6 (15.0) 64.7 (18.5) 64.8 (15.0)
Final VA, mean letters (SD) 67.6 (18.7) 64.6 (16.9) 63.4 (21.2) 65.3 (16.1) 65.1 (20.4) 66.2 (13.6)
Days til switch, median (Q1, Q3) 189.5 (158.5,
276.5)
202 (147, 287) 283 (189, 382) 290 (175, 444.5) 381.5 (277.75,
728)
308 (206, 588.5)
Injections til switch, median (Q1,
Q3)
7 (6.25, 10) 7 (6, 10) 10 (7, 12) 10 (7, 13) 11 (6, 16) 13 (7.75, 19.75)
Injections per year Pre switch,
median (Q1, Q3)
11.6 (11.2, 12.0) 12.4 (11.3, 13) 11.5 (10.3, 11.9) 12.0 (10.0, 12.7) 11.0 (9.4, 11.6) 11.7 (9.4, 12.7)
Injections per year Post-switch,
median (Q1, Q3)
10.6 (9.0, 11.5) 12.0 (10.4, 13.0) 10.2 (9.2, 11.4) 10.9 (8.0, 12.3) 10.0 (8.0, 10.9) 10.7 (8.7, 11.9)
Total injections, median (Q1,
Q3)
12 (12, 12) 13 (11, 14) 22 (20, 23) 22 (18, 25) 31 (25, 35) 30 (29, 33)
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modest reduction and may have
occurred over time in any case.
Interestingly patients who did not
switch therapy received far fewer (me-
dian [Q1, Q3]) injections than the
switchers (9 [8, 11] versus 13 [11, 13]
at 12 months; 15 [11, 19] versus 22 [18,
24] at 24 months; and 20 [14.5, 24]
versus 31 [26, 35] at 36 months) so it
seems that the most important motiva-
tion for switching was to reduce the
injection load for patients in need of a
high frequency of injections.
General cardiovascular or other
complications were not recorded in
the register, but the number of ocular
adverse events, like endophthalmitis,
was very low, and seemed not related
to the total number of injections.
Endorsed by ICHOM, FRB! pro-
vides many clinically helpful features
such as a highly informative overview
in a single graph of each individual
patients treatment journey for as long
as they are treated, which may be over
a decade.(Invernizzi et al. 2019; Gillies
et al., 2020a,2020b) Features such as
the course of visual acuity over time,
the time of injections provided, the
drug(s) used and the grading of lesion
activity at each visit were very helpful
for the decision-making process for
retreatment and the choice of drug.
Some centres changed their treatment
regimens after seeing the outcomes
from the other participating centres in
order to improve their own.
Reducing the burden of data entry is
essential to integrating a registry into
the clinical workflow. The FRB! data
set is the minimum, patient-centred
dataset that was identified by ICHOM
for macular degeneration (Rodrigues
et al. 2016). Still, many participating
ophthalmologists preferred to enter the
data after the outpatient clinic rather
than when they saw the patient as the
system is intended. Some centres
stopped participating or only entered
a limited the number of patients
because of the extra time requirements.
This is further evidence that the Dutch
FRB! practitioners may not completely
represent the Netherlands.
Single point data entry, in which all
data already registered in the electronic
patient file (EPF) is shared with the
FRB! server, will make it easier to
participate in registries although the
minimum dataset will still have to be
entered. The EPF needs to be adjusted
to include all the FRB! required data in
the correct format. Technically this can
be realized; however, privacy legisla-
tion in Europe complicates this process
especially because the central server is
in Australia, outside the European
Union. One prerequisite is an agree-
ment between the participating centre
and the FRB! organization in line with
privacy and data protection legislation,
and another is an informed consent to
be signed by all patients describing the
details and the go of the registry.
Conclusion
The outcomes of starting anti-VEGF
treatment for nAMD with beva-
cizumab, as is mandatory in the
Netherlands, appear to be at least as
good as those with either ranibizumab
or aflibercept, but at a cost of more
frequent injections, and visits, and
more frequent switching treatment to
a second drug. This study showed the
power of using data from routine
clinical practice acquired through a
quality registry to make useful com-
parisons and benchmark countries and
individual practices.
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